This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Targets for Therapeutics

Robert M. Post, MD
Biological Psychiatry Branch National Institute of Mental Health National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Arch Gen Psychiatry. 1997;54(7):607-608.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THIS ISSUE of the ARCHIVES, the article by Duman and colleagues¹ helps clarify the next layer of understanding of the neurobiology of depression and, ultimately, brings to light more powerful and selective treatment interventions. As in the catecholamine and indoleamine hypotheses of the 1960s, Duman et al appropriately rely heavily on a pharmacological bridge to better understand potential alterations in depression based on the effects of antidepressant medications. In addition, microstructural alterations in the brains of patients with depression have begun to be reported, with initial reports of increased expression of corticotropin-releasing hormone in the brains of suicide victims who had depression; increased size of the pituitary and adrenal glands; and a variety of findings concerning receptor, peptide, and structural alterations in the hippocampus, including preliminary findings of decreased hippocampal size as a function of duration of prior depressions.² It is against this background that tracing the effects . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?